Lawsuit Information Center

March 15, 2026

Paragard IUD Lawsuit Settlement Amounts

Our lawyers are handling Paragard IUD removal lawsuits in all 50 states. Over 3,500 women have filed a Paragard IUD lawsuit claiming that they were injured when a design defect IUD caused it to fracture during removal and leave foreign objects inside their bodies.

These lawsuits allege the Paragard intrauterine device breaks upon removal because it is made with inflexible plastic and degrades before the device expires. Over 3,000 lawsuits have been lodged against Teva Pharmaceutical and CooperSurgical by women who encountered issues such as breakage during removal or implantation, or other complications associated with the Paragard birth control device.

This page provides the latest update on the 2026 Paragard lawsuit. Our lawyers also speculate on the potential settlement value of a Paragard lawsuit if the litigation is resolved through a global settlement with the manufacturers. When could there be a settlement? Soon. These cases could be resolved by the end of 2026, with victims receiving payment in 2026 if the settlement is finalized quickly. Is that the most likely scenario? We are cautiously optimistic but after the first trial loss in February 2026,

March 14, 2026

Olympus Duodenoscope Infection Lawsuit

by Ronald V. Miller, Jr.

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died. The infections were caused by drug-resistant bacteria that no antibiotic could reliably kill. The patients had gone into the hospital for routine diagnostic procedures–gallstone evaluations, pancreatic biopsies, bile duct imaging–and came out with infections that would destroy their organs, land them in intensive care for months, or kill them outright.

The remarkable part is not that it happened. Medical devices fail. Infections occur. What makes the Olympus duodenoscope litigation extraordinary is that the company knew. Olympus knew its scopes could not be adequately cleaned. Olympus knew that bacteria were surviving the sterilization process and spreading from patient to patient. Olympus knew that people were dying. And for years, the company did almost nothing.

This page explains what went wrong, why it went wrong, and the legal options available to patients and families harmed by contaminated Olympus scopes. It is long. It is detailed. It is written for people who want to understand not just the claims being filed, but the science, the regulatory failures, and the corporate decisions that turned a solvable engineering problem into a public health catastrophe.

March 14, 2026

Depo Provera Lawsuit Settlements

by Ronald V. Miller, Jr.

This page is for victims considering filing a Depo-Provera lawsuit. Our lawyers provide the latest updates on these claims, explain the litigation process, and predict Depo Provera settlement amounts.

A new scientific study has provided stunning evidence that using Depo-Provera can cause brain tumors. Women who used Depo-Provera and subsequently developed a meningioma brain tumor can file a Depo-Provera lawsuit seeking financial compensation. This new evidence is leading to a wave of Depo-Provera lawsuits nationwide.

Our lawyers are speaking to over 100 women a week who used Depo-Provera and have been diagnosed with meningioma. Our law firm is committed to this litigation and handling Depo-Provera lawsuits for women who had at least two injections and were later diagnosed with a meningioma brain tumor. If you meet these criteria, we will make the process of signing up for this litigation easy for you. Contact our Depo-Provera lawyers today at 800-553-8082 or contact us online.

March 14, 2026

Social Media Addiction Lawsuit

by Ronald V. Miller, Jr.

This page is about social media addiction lawsuits and who is eligible to bring a claim. Our lawyers also provide the latest news on social media class action lawsuits.

The problem that led to social media lawsuits is that millions of people, too many of whom are children, are addicted to social media platforms such as Facebook, Instagram, Snapchat, and others. For these vulnerable users, social media addiction can be very harmful and lead to things like eating disorders, depression, and, in some cases, suicide.

Now, these companies are facing a wave of new social media lawsuits alleging that they knowingly designed the algorithms of their platforms to lure young people into harmful addictions.

March 14, 2026

Ozempic Lawsuit

by Ronald V. Miller, Jr.

Our lawyers are investigating Ozempic lawsuits for patients with NAION, gastroparesis or gastrointestinal conditions, including bowel obstruction or cyclic vomiting syndrome.

Ozempic is the popular brand name for semaglutide, a prescription drug approved for the treatment of type 2 diabetes. As we all know, Ozempic is also commonly used as a weight management drug. Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis.

March 13, 2026

Philips CPAP Lawsuit Settlement

by Ronald V. Miller, Jr.

Our law firm was handling Philips CPAP machine lawsuits for injuries from the recalled Philips CPAP machine.

The Philips recall covered an estimated 3.5 million sleep apnea devices. A CPAP class action lawsuit with thousands of plaintiffs has been consolidated into a multi-district litigation (MDL-1230). So, every Philips CPAP lawsuit in federal court—filed in New York, California, Texas, or wherever—was consolidated in federal court in Pennsylvania.

After the settlement, we are no longer reviewing new cases.

March 11, 2026

Monsanto Roundup Lawsuit Update

by Ronald V. Miller, Jr.

In this post, our Roundup lawyers will give you:

An update on where things stand in the Roundup class action lawsuit in February 2026
The likely direction the Roundup litigation will take moving forward, and

March 11, 2026

Uber Sexual Assault Lawsuits

by Ronald V. Miller, Jr.

Uber is facing one of the largest waves of passenger sexual assault lawsuits in U.S. history. Survivors across the country allege that Uber drivers sexually assaulted them and that the company is legally responsible because it failed to screen drivers properly, ignored prior complaints, and did not implement basic safety measures.

These claims are now consolidated in In re: Uber Technologies Inc., Passenger Sexual Assault Litigation (MDL No. 3084) in the Northern District of California. As of February 2026, more than 3,700 plaintiffs in 30 states have joined the MDL, with this number expected to continue rising throughout 2025.

The first MDL trial started in January 2026, the jury came back in early February with an $8.5 million verdict. Our lawyers believe these are exceptionally strong cases. The evidence points to a pattern: repeated warnings about dangerous drivers, no action from Uber, and preventable assaults that followed. In the courtroom, that is the kind of timeline juries understand and respond to. It is also the kind of fact pattern that can lead to substantial Uber sexual assault settlement amounts.

March 11, 2026

Camp Lejeune Lawsuit News and Updates

by Ronald V. Miller, Jr.

This page provides Camp Lejeune lawsuit updates. Our lawyers are still working to give the latest update on the litigation, even though we are no longer taking new cases. Why? Because there is little information out there, and we are staying with victims, including those we do not represent, until the end.

We have also recently reopened the comments below to answer any questions you may have or simply give you a chance to share your thoughts.

March 10, 2026

Dupixent Lawsuit for T-Cell Lymphoma

by Ronald V. Miller, Jr.

Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other inflammatory conditions. It works by targeting specific immune pathways involved in allergic inflammation. For many patients with moderate to severe eczema, Dupixent has provided relief where topical medications failed. As a result, it has become one of the most widely prescribed biologic drugs for skin and respiratory conditions.

But for a growing number of patients, the experience with Dupixent has been very different. Over the past several years, doctors and researchers have reported cases in which patients treated with Dupixent were later diagnosed with cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma that primarily affects the skin. These reports have led to increasing scrutiny of whether Dupixent can worsen, accelerate, or mask CTCL in certain patients.

Lawyers across the country are now reviewing Dupixent lawsuits on behalf of patients who developed CTCL, mycosis fungoides, or Sézary syndrome after receiving Dupixent injections.